ERBB2 and breast carcinoma: Compared to trastuzumab (first line chemotherapeutics agent used in HER2-positive breast cancer), regarding to the tumor cell metastasis to liver and lung, trastuzumab had no significant inhibitory effect on breast cancer metastasis in MDA-MB-361 tumor bearing mice model.